Autobahn Therapeutics Secures $200M in Series C Funding for Revolutionary CNS Drug Development

Autobahn Therapeutics, Inc., an innovative biotechnology company dedicated to transforming the lives of those affected by central nervous system (CNS) disorders, has successfully raised $200 million in its latest funding round. This significant investment will propel the company forward in its quest to harness the human body's regenerative power to combat the progressive and debilitating nature of CNS disorders. With a focus on developing novel, small molecule therapies that target the brain, Autobahn Therapeutics aims to transcend the limitations of existing treatments by restoring the brain to a healthier state. The successful funding round will further enhance the development of Autobahn’s promising pipeline, which includes ABX-002—a centrally-penetrant thyroid hormone receptor beta (TRβ) agonist. This innovative compound is being explored as a potential adjunctive treatment for individuals suffering from major depressive disorder and bipolar disorder depression, addressing critical unmet needs in neuropsychiatry. The company’s unique approach combines deep knowledge of human biology with brain-targeting chemistry, setting a robust foundation for innovative and effective therapies. With the support of this new funding, Autobahn Therapeutics is poised to make significant strides in CNS drug development, aiming to break the cycle of limited innovation and high failure rates that have long plagued the industry. This funding marks not just a milestone for Autobahn but also offers hope for patients and families seeking better therapeutic options in their fight against CNS disorders. As Autobahn continues to pioneer groundbreaking therapies, the future looks brighter for those impacted by these challenging conditions.